Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. (Q44546647)

4 December 2017

title

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. (English)

1 reference

single-nucleotide polymorphism

4 December 2017

main subject

1 reference

1 reference

1 reference

4 December 2017

J J Farrell

1 reference

4 December 2017

K Bae

1 reference

4 December 2017

J Wong

1 reference

4 December 2017

C Guha

1 reference

4 December 2017

H Elsaleh

1 reference

4 December 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

The Pharmacogenomics Journal

4 December 2017

1 reference

inferred from page(s)

published in

1 reference

4 December 2017

1 reference

4 December 2017

1 reference

4 December 2017

page(s)

395-403

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Adjuvant therapy for pancreatic cancer: current status, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2011.22

21 January 2018

Identifiers

DOI

10.1038/TPJ.2011.22

1 reference

Dimensions Publication ID

4 December 2017

1005674477

0 references

1 reference